Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.56 |
| ▸ | CCND1 | P24385 | 5/20 | 0.56 |
| ▸ | CCND3 | P30281 | 4/20 | 0.56 |
| ▸ | CCND2 | P30279 | 2/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11977230 | 0.84 | CDK4 (0.61) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL4191054 | 0.84 | CDK6 (0.57) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL11977129 | 0.83 | CDK4 (0.55) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL11977132 | 0.82 | CDK4 (0.56) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL11977131 | 0.82 | CDK4 (0.56) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL7712824 | 0.80 | CDK4 (0.67) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL7706828 | 0.79 | CDK4 (0.73) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL7706831 | 0.78 | CDK4 (0.72) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL11977130 | 0.74 | CDK4 (0.59) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL11977081 | 0.73 | CDK4 (0.61) | CDK4CCND1CCND3CCND2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCND3 782/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCND3 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.